Adam A. Walters
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Adam A. Walters has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Khuloud Taysir Al-Jamal
Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King’s College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom
4 shared publications Julie Tzu-Wen Wang
Institute of Pharmaceutical Science, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, UK
3 shared publicationsYue Qin
Institute of Pharmaceutical Science Faculty of Life Sciences & Medicine King's College London Franklin‐Wilkins Building, 150 Stamford Street London SE1 9NH UK
3 shared publicationsAmer F. Saleh
Cell Therapy Safety Clinical Pharmacology and Safety Sciences BioPharmaceuticals R&D AstraZeneca Cambridge CB2 0AA UK
1 shared publication- Andrew J. Pollard
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK
1 shared publication Calvin C. L. Cheung
JC STEM Lab of Nanomedicine for Advanced Therapy Department of Pharmacology and Pharmacy LKS Faculty of Medicine The University of Hong Kong Hong Kong SAR China
1 shared publication
Latest Publications
- Open Access
- 12 December 2025
- Published by Wiley in Small Science
- Vol. 6 (1)
Triplet RNA Lipid Nanoparticles for Locoregional Cancer Immunotherapy
Ionizable lipid nanoparticles (LNPs) are a proven means of delivering nucleic acid‐based therapeutics. This project aims to expand the LNP platform for the delivery of immunostimulatory polyinosinic‐polycytidylic acid (pIpC). It is demonstrated that pIpC could be successfully incorporated into LNPs with minimal modification to existing protocols. LNPs encapsulating pIpC (pIpC‐LNPs) exhibit a spherical shape with a diameter under 200 nm. When administered intratumorally, pIpC‐LNPs are significantly more potent than the soluble adjuvant, resulting in complete remission in 25% of tumors. To identify potential synergistic targets, T cell activation markers are screened following pIpC‐LNP treatment. OX40 and CD27 are strongly upregulated and associated with intratumoral pIpC‐LNP administration. Furthermore, direct treatment of a cancer cell line with pIpC‐LNPs results in upregulation of the immunosuppressive PDL1. To develop a comprehensive RNA‐based immunotherapeutic strategy, LNPs are formulated with mRNAs encoding CD70 (the CD27 ligand) and OX40L, or with siRNA targeting PDL1, and are evaluated in combination. Tumor growth reduction is observed when pIpC‐LNPs are combined with siPDL1. This study demonstrates the potential of a triplet RNA platform‐comprising immunostimulatory RNA, mRNA, and siRNA, delivered via a single versatile LNP. The data support development of pIpC‐LNPs as potent intratumoral therapeutics and highlight several potential synergistic targets.
- 12 December 2025
- Published by Wiley in Small Science
- Vol. 6 (1)
Open AccessTriplet RNA Lipid Nanoparticles for Locoregional Cancer Immunotherapy
Ionizable lipid nanoparticles (LNPs) are a proven means of delivering nucleic acid‐based therapeutics. This project aims to expand the LNP platform for the delivery of immunostimulatory polyinosinic‐polycytidylic acid (pIpC). It is demonstrated that pIpC could be successfully incorporated into LNPs with minimal modification to existing protocols. LNPs encapsulating pIpC (pIpC‐LNPs) exhibit a spherical shape with a diameter under 200 nm. When administered intratumorally, pIpC‐LNPs are significantly more potent than the soluble adjuvant, resulting in complete remission in 25% of tumors. To identify potential synergistic targets, T cell activation markers are screened following pIpC‐LNP treatment. OX40 and CD27 are strongly upregulated and associated with intratumoral pIpC‐LNP administration. Furthermore, direct treatment of a cancer cell line with pIpC‐LNPs results in upregulation of the immunosuppressive PDL1. To develop a comprehensive RNA‐based immunotherapeutic strategy, LNPs are formulated with mRNAs encoding CD70 (the CD27 ligand) and OX40L, or with siRNA targeting PDL1, and are evaluated in combination. Tumor growth reduction is observed when pIpC‐LNPs are combined with siPDL1. This study demonstrates the potential of a triplet RNA platform‐comprising immunostimulatory RNA, mRNA, and siRNA, delivered via a single versatile LNP. The data support development of pIpC‐LNPs as potent intratumoral therapeutics and highlight several potential synergistic targets.
- Open Access
- 29 March 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 369, 251-265
Plasmid DNA ionisable lipid nanoparticles as non-inert carriers and potent immune activators for cancer immunotherapy
- 29 March 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 369, 251-265
Open AccessPlasmid DNA ionisable lipid nanoparticles as non-inert carriers and potent immune activators for cancer immunotherapy
- Open Access
- 22 October 2021
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 15 (11) , 17549-17564
Nanoparticle-Mediated In Situ Molecular Reprogramming of Immune Checkpoint Interactions for Cancer Immunotherapy
Immune checkpoint blockade involves targeting immune regulatory molecules with antibodies. Preclinically, complex multiantibody regimes of both inhibitory and stimulatory targets are a promising candidate for the next generation of immunotherapy. However, in this setting, the antibody platform may be limited due to excessive toxicity caused by off target effects as a result of systemic administration. RNA can be used as an alternate to antibodies as it can both downregulate immunosuppressive checkpoints (siRNA) or induce expression of immunostimulatory checkpoints (mRNA). In this study, we demonstrate that the combination of both siRNA and mRNA in a single formulation can simultaneously knockdown and induce expression of immune checkpoint targets, thereby reprogramming the tumor microenvironment from immunosuppressive to immunostimulatory phenotype. To achieve this, RNA constructs were synthesized and formulated into stable nucleic acid lipid nanoparticles (SNALPs); the SNALPs produced were 140–150 nm in size with >80% loading efficiency. SNALPs could transfect macrophages and B16F10 cells in vitro resulting in 75% knockdown of inhibitory checkpoint (PDL1) expression and simultaneously express high levels of stimulatory checkpoint (OX40L) with minimal toxicity. Intratumoral treatment with the proposed formulation resulted in statistically reduced tumor growth, a greater density of CD4+ and CD8+ infiltrates in the tumor, and immune activation within tumor-draining lymph nodes. These data suggest that a single RNA-based formulation can successfully reprogram multiple immune checkpoint interactions on a cellular level. Such a candidate may be able to replace future immune checkpoint therapeutic regimes composed of both stimulatory- and inhibitory-receptor-targeting antibodies.
- 22 October 2021
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 15 (11) , 17549-17564
Open AccessNanoparticle-Mediated In Situ Molecular Reprogramming of Immune Checkpoint Interactions for Cancer Immunotherapy
Immune checkpoint blockade involves targeting immune regulatory molecules with antibodies. Preclinically, complex multiantibody regimes of both inhibitory and stimulatory targets are a promising candidate for the next generation of immunotherapy. However, in this setting, the antibody platform may be limited due to excessive toxicity caused by off target effects as a result of systemic administration. RNA can be used as an alternate to antibodies as it can both downregulate immunosuppressive checkpoints (siRNA) or induce expression of immunostimulatory checkpoints (mRNA). In this study, we demonstrate that the combination of both siRNA and mRNA in a single formulation can simultaneously knockdown and induce expression of immune checkpoint targets, thereby reprogramming the tumor microenvironment from immunosuppressive to immunostimulatory phenotype. To achieve this, RNA constructs were synthesized and formulated into stable nucleic acid lipid nanoparticles (SNALPs); the SNALPs produced were 140–150 nm in size with >80% loading efficiency. SNALPs could transfect macrophages and B16F10 cells in vitro resulting in 75% knockdown of inhibitory checkpoint (PDL1) expression and simultaneously express high levels of stimulatory checkpoint (OX40L) with minimal toxicity. Intratumoral treatment with the proposed formulation resulted in statistically reduced tumor growth, a greater density of CD4+ and CD8+ infiltrates in the tumor, and immune activation within tumor-draining lymph nodes. These data suggest that a single RNA-based formulation can successfully reprogram multiple immune checkpoint interactions on a cellular level. Such a candidate may be able to replace future immune checkpoint therapeutic regimes composed of both stimulatory- and inhibitory-receptor-targeting antibodies.
- Open Access
- 1 June 2020
- Published by Elsevier in Journal of Controlled Release
- Vol. 322, 519-529
Evaluation of cell surface reactive immuno-adjuvant in combination with immunogenic cell death inducing drug for in situ chemo-immunotherapy
- 1 June 2020
- Published by Elsevier in Journal of Controlled Release
- Vol. 322, 519-529
Open AccessEvaluation of cell surface reactive immuno-adjuvant in combination with immunogenic cell death inducing drug for in situ chemo-immunotherapy
- Open Access
A potent neutralizing epitope of limited variability in the head domain of haemagglutinin as a novel influenza vaccine target
Antigenic targets of influenza vaccination are currently seen to be polarised between (i) highly immunogenic (and protective) epitopes of high variability, and (ii) conserved epitopes of low immunogenicity. This requires vaccines directed against the variable sites to be continuously updated, with the only other alternative being seen as the artificial boosting of immunity to invariant epitopes of low natural efficacy. However, theoretical models suggest that the antigenic evolution of influenza is best explained by postulating the existence of highly immunogenic epitopes of limited variability. Here we report the identification of such an epitope of limited variability in the head domain of the H1 haemagglutinin protein. We show that the epitope mediates immunity to historical influenza strains not previously seen by a cohort of young children. Furthermore, vaccinating mice with these epitope conformations can induce immunity to all the human H1N1 influenza strains that have circulated since 1918. The identification of epitopes of limited variability offers a mechanism by which a universal influenza vaccine can be created; these vaccines would also have the potential to protect against newly emerging influenza strains.
Open AccessA potent neutralizing epitope of limited variability in the head domain of haemagglutinin as a novel influenza vaccine target
Antigenic targets of influenza vaccination are currently seen to be polarised between (i) highly immunogenic (and protective) epitopes of high variability, and (ii) conserved epitopes of low immunogenicity. This requires vaccines directed against the variable sites to be continuously updated, with the only other alternative being seen as the artificial boosting of immunity to invariant epitopes of low natural efficacy. However, theoretical models suggest that the antigenic evolution of influenza is best explained by postulating the existence of highly immunogenic epitopes of limited variability. Here we report the identification of such an epitope of limited variability in the head domain of the H1 haemagglutinin protein. We show that the epitope mediates immunity to historical influenza strains not previously seen by a cohort of young children. Furthermore, vaccinating mice with these epitope conformations can induce immunity to all the human H1N1 influenza strains that have circulated since 1918. The identification of epitopes of limited variability offers a mechanism by which a universal influenza vaccine can be created; these vaccines would also have the potential to protect against newly emerging influenza strains.